Guilin Sanjin: BC006 monoclonal antibody injection new indication approved for clinical trials
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, Guilin Sanjin announced that its holding subsidiary, Baochuan Biopharmaceutical Technology (Shanghai) Co., Ltd. (referred to as "Baochuan Biopharma"), has received the clinical trial approval for BC006 monoclonal antibody injection issued by the National Medical Products Administration, allowing the commencement of clinical trials for the indication of idiopathic pulmonary fibrosis
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments